Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).
B. Lan, Ye-Hui Shi, Xi-Ying Shao et al.· The Lancet· 0 citations
Importance
Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer.
Objective
To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients...
Y. Fan, Yun-Jiang Liu, Yong-Sheng Wang et al.· Journal of the American Medi...· 1 citation
PURPOSE
To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC).
METHODS
In this phase III, open-label, multicenter trial (ClinicalTrials.gov...
Jian Zhang, Q. Ouyang, Qing-Yuan Zhang et al.· Journal of Clinical Oncology· 0 citations
Patients with HER2-positive advanced breast cancer with liver metastases (BCLM) have poor prognosis. Study RC48-C006 is a prospective, open-label, multi-center, randomized phase 2/3 trial (ClinicalTrials.gov identifier, NCT03500380). Based on the phase 2 results, the phase 3 stage was initiated to evaluate disitamab ve...
